BridgeMD
New treatment option for All Types of Metastatic Solid Malignancy
Official title Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.
ClinicalTrials.gov ID: NCT06550687
What this study is testing
- What it's testing
- Currently, the EXOMA2 study (NCT04614480) offers earlier and more comprehensive exome analysis in the management of cancer patients than EXOMA. Based on the active EXOMA2 patient file, the INFOGene study offers the opportunity to study patient-physician communication, to assess patient preferences with regard to different information modalities concerning theranostic exome analysis, and to reflect on information modalities to ensure optimal patient comprehension of the information provided.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient identified for inclusion in the EXOMA 2 study (exome analysis request)
- Available to receive different types of information
- Fluent in French
- No prior oncogenetic consultation
- Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study
You likely can't join if
- Patient who refused to participate in the EXOMA2 study (for phase 3 patients only)
- Has a psychiatric, cognitive or neurological disorder that makes participation impossible
- Working in the field of genetics
See the full eligibility criteria
- Patient identified for inclusion in the EXOMA 2 study (exome analysis request)
- Available to receive different types of information
- Fluent in French
- No prior oncogenetic consultation
- Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study
- Authorizing audio recording of consultations and interviews
- Patient who refused to participate in the EXOMA2 study (for phase 3 patients only)
- Has a psychiatric, cognitive or neurological disorder that makes participation impossible
- Working in the field of genetics
The study team makes the final eligibility decision.
Where it's taking place
- Dijon, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dijon, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.